Please provide your email address to receive an email when new articles are posted on . The angiotension receptor blocker candesartan has demonstrated the ability to significantly regress diabetic ...

The aim of the present study was to investigate the pharmacokinetics and short-term tolerability of the angiotensin II type 1 receptor antagonist candesartan cilexetil in patients receiving ...

Treatment with candesartan can increase regression of retinopathy in type 2 diabetes and reduce incidence of retinopathy in type 1 diabetes. These are among the conclusions of the DIRECT studies ...

An 8-week, multicenter, double-blind, randomized, parallel-group, forced-titration study was conducted to evaluate the antihypertensive efficacy of candesartan vs. losartan in 654 hypertensive ...

Bilous and colleagues report that treatment with the angiotensin-receptor blocker candesartan does not prevent microalbuminuria in patients with type 1 or type 2 diabetes mellitus who are ...

In a comparison of the angiotensin II receptor blockers (ARBs) candesartan and losartan, used by patients with heart failure, candesartan was associated with a lower risk of death at 1 and 5 years ...

To determine whether the pharmacological characteristics of candesartan offer advantages over the first in class ARB, losartan, with respect to anti-hypertensive efficacy, we undertook a meta ...